Wong George K C, Lam Christopher W K, Chan Mathew T V, Gin Tony, Poon Wai S
Division of Neurosurgery, The Chinese University of Hong Kong, China.
Magnes Res. 2009 Jun;22(2):60-5.
Preliminary evidence has suggested that magnesium sulfate infusion reduces delayed ischemic neurological deficit and improves clinical outcome after aneurysmal subarachnoid hemorrhage. However, little is known about its site of action in vivo. We studied 22 aneurysmal subarachnoid hemorrhage patients with or without magnesium sulfate infusion for 10-14 days. Thirteen patients had external ventricular drains inserted for hydrocephalus and daily cerebrospinal fluid magnesium levels were measured. For patients given magnesium sulfate infusion, the aim was to raise the plasma magnesium level to double the baseline level. We found that the magnesium sulfate infusion bought an 11% to 21% increase in cerebrospinal fluid magnesium. The elevation of cerebrospinal fluid magnesium was sustained for at least nine days. Whether this mild elevation in cerebrospinal fluid magnesium level was adequate for neuroprotection awaits the results of ongoing clinical trials.
初步证据表明，静脉输注硫酸镁可减少动脉瘤性蛛网膜下腔出血后的迟发性缺血性神经功能缺损并改善临床结局。然而，其在体内的作用部位尚不清楚。我们研究了22例接受或未接受硫酸镁输注10 - 14天的动脉瘤性蛛网膜下腔出血患者。13例因脑积水插入了脑室外引流管，并每日测量脑脊液镁水平。对于接受硫酸镁输注的患者，目标是将血浆镁水平提高至基线水平的两倍。我们发现，输注硫酸镁使脑脊液镁水平升高了11%至21%。脑脊液镁水平的升高持续了至少九天。脑脊液镁水平的这种轻度升高是否足以实现神经保护，还有待正在进行的临床试验的结果。
